Tumor-Specific Major Histocompatibility-II Expression Predicts Benefit to Anti–PD-1/L1 Therapy in Patients With HER2-Negative Primary Breast Cancer
Abstract
Immunotherapies targeting PD-1/L1 enhance pathologic complete response (pCR) rates when added to standard neoadjuvant chemotherapy (NAC) regimens in early-stage triple-negative, and possibly high-risk estrogen receptor–positive breast cancer. However, immunotherapy has been associated with significant toxicity, and most patients treated with NAC do not require immunotherapy to achieve pCR. Biomarkers discerning patients benefitting from the addition of immunotherapy from those who would achieve pCR to NAC alone are clearly needed. In this study, we tested the ability of MHC-II expression on tumor cells, to predict immunotherapy-specific benefit in the neoadjuvant breast cancer setting.
Document Details
- Document Type
- Pub Defense Publication
- Publication Date
- Jul 27, 2021
- Source ID
- 10.1158/1078-0432.ccr-21-0607
Entities
People
- Eli Lilly
- Emanuel Petricoin
- Henry Gomez
- Julia D. Wulfkhule
- Justin M. Balko
- Kim R M Blenman
- Lajos Pusztai
- Margaret L Axelrod
- Melinda E. Sanders
- Na Luo
- Paula González Ericsson
- Quanhu Sheng
- Rosa I. Gallagher
- Violeta Sanchez
- Xiaopeng Sun
Organizations
- Eisai
- Foundation for the National Institutes of Health
- Gateway for Cancer Research
- George Mason University
- Nankai University
- National Cancer Institute
- National Institutes of Health
- Pfizer
- Susan G. Komen for the Cure
- The Breast Cancer Research Foundation
- United States Department of Defense
- Vanderbilt University
- Vanderbilt University Medical Center
- Vanderbilt-Ingram Cancer Center
- Yale University